CD8A and ovarian cancer: CXCL9 has recently been identified as a critical mediator of anti-tumor T cell responses, and high CXCL9 levels are associated with increased numbers of CD8 positive T cells in ascites and better prognosis in ovarian cancer patients [39, 40].